Table 3. Sensitivity of NCCN and Risk Model Prediction Estimates for Screening Eligibility Among Patients With Lung Cancer in the Inflammation, Health, Ancestry, and Lung Epidemiology Study.
| Model | Patients, No. (%) | White vs African American patients | |||
|---|---|---|---|---|---|
| All (N = 912) | White (n = 625) | African American (n = 287) | RR (95% CI) | P value | |
| NLST | 412 (45) | 298 (48) | 114 (40) | 1.2 (1.0-1.4) | .03 |
| USPSTF 2013 | 445 (49) | 324 (52) | 121 (42) | 1.2 (1.1-1.4) | .007 |
| NCCN group 2 | 563 (62) | 417 (67) | 146 (51) | 1.3 (1.2-1.4) | <.001 |
| USPSTF 2021 | 590 (65) | 408 (65) | 182 (63) | 1.0 (0.9-1.1) | .64 |
| PLCOm2012 ≥1.51% | 619 (68) | 427 (68) | 192 (67) | 1.0 (0.9-1.1) | .73 |
Abbreviations: NCCN, National Comprehensive Cancer Network; NLST, National Lung Screening Trial; PLCOm2012, 2012 modification of the model from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial; RR, relative risk; USPSTF, US Preventive Services Task Force.